1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Generics

Lack Of Priority? No ANDAs Approved Using Expedited Pathway In FY 2018

 
• By Derrick Gingery

US FDA also refused to receive many priority generic drug applications, suggesting the expedited pathway may not be working as intended quite yet.

3d different tablets and pills on a white background with question marks

The US FDA did not approve any priority assessment ANDAs in fiscal year 2018, but did push a few applications through another expedited pathway, signaling that industry may not fully understand the new system intended to help speed generic drugs to market.

Priority assessments were introduced in 2017 as part of the FDA Reauthorization Act. Under the pathway, sponsors can receive an...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

US FDA ANDA Priority Pilot ‘Practically Unusable’ Without Tweaks, AAM CEO Says

 
• By Sarah Karlin-Smith

Association for Accessible Medicines CEO John Murphy told the Pink Sheet that the FDA may need to consider phasing in the requirements for the new ANDA priority voucher incentive program if it wants sponsors to apply in the near-term.

Oz: CMS Developing Plans To Incentivize Domestic Manufacturing

 
• By Sarah Karlin-Smith

The Trump Administration’s efforts to encourage more US-based pharmaceutical manufacturing have largely centered on FDA plans and Trump’s threats of tariffs and Most Favored Nation pricing, but Oz hinted Medicare and Medicaid soon may soon announce new incentives.

GDUFA IV Talks Begin, Embracing Traditional Process

 
• By Derrick Gingery

The introductory meeting did not suggest changes to the expected schedule and operations for renewing the generic drug user fee, said AAM’s Giuseppe Randazzo.

US FDA’s ANDA Prioritization Pilot Encouraging Production Onshoring

 
• By Dave Wallace

The latest incentive for firms to move manufacturing to the US is an FDA pilot program that will prioritize the review of US-manufactured and tested ANDA products.

More from Biosimilars & Generics

Biosimilar Interchangeability Guidance Eliminating Switching Studies Coming Soon

 
• By Cathy Kelly

The guidance is part of the FDA’s effort to encourage more biosimilar development by streamlining approval requirements and lowering development costs.

US FDA’s Makary Wants Lower Biosimilar Launch Prices As Clinical Study Mandate Changed

 
• By Derrick Gingery

The new guidance says comparative clinical trials are not a prerequisite for all biosimilars, a notable step for the FDA, but the commissioner added that biosimilar prices should be significantly lower than the reference product at launch.

Biosimilars: US FDA Regulatory Science Research ROI Still To Be Determined

 
• By Derrick Gingery

FDA officials said the pilot program needs more time to determine its return on investment as user fee renewal talks near.